Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial - Pautier, P; Italiano, A; Piperno-Neumann, S (Lancet Oncol, 2022)
et al.